gynaecological tumours prof.dr.póka róbert female genital cancer incidence (n/100.000...
TRANSCRIPT
![Page 1: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/1.jpg)
Gynaecological tumoursGynaecological tumours
Prof.Dr.Póka RóbertProf.Dr.Póka Róbert
![Page 2: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/2.jpg)
Female genital cancer Female genital cancer incidenceincidence
(N/100.000 population/year) (N/100.000 population/year) in 2008in 2008Eurostat, 2010Eurostat, 2010
EUREUR HUHU
BreastBreast 88,488,4 78,778,7
CervixCervix 12,812,8 19,519,5
EndometriumEndometrium 16,716,7 17,717,7
OvaryOvary 13,713,7 13,713,7
![Page 3: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/3.jpg)
Female genital cancer Female genital cancer mortality mortality
(N/100.000population/year) (N/100.000population/year) in 2008in 2008Eurostat, 2010Eurostat, 2010
EUREUR HUHU
BreastBreast 24,324,3 22,622,6
CervixCervix 5,25,2 5,75,7
EndometriumEndometrium 3,83,8 3,63,6
OvaryOvary 7,97,9 8,38,3
![Page 4: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/4.jpg)
![Page 5: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/5.jpg)
Cervical cancer treatment dilemmas
•Early stg disease - Op, advanced - Rad•Rad limited by normal tissue tolerance•Clinically early might be biologically advanced•In early stg Op and Rad results are similar
![Page 6: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/6.jpg)
Indications and types of Indications and types of surgical treatmentsurgical treatment
Preserve fertilityPreserve fertility Classical Wertheim-Meigs operationClassical Wertheim-Meigs operation Neoadjuvant chemo followed by Neoadjuvant chemo followed by
radical surgeryradical surgery Surgery for recurrent diseaseSurgery for recurrent disease
![Page 7: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/7.jpg)
Trachelectomy’s necessityTrachelectomy’s necessity
Changing morbidityChanging morbidityChanging demographyChanging demographyChanging technologyChanging technology
![Page 8: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/8.jpg)
Prerequisites of Prerequisites of trachelectomytrachelectomy
Ca.cx.ut. Std. Ia1,Ia2,Ib1Ca.cx.ut. Std. Ia1,Ia2,Ib1Parametrial spread excluded by CT, Parametrial spread excluded by CT, MRMRFitness for surgeryFitness for surgeryFertility preservation is desiredFertility preservation is desired
![Page 9: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/9.jpg)
![Page 10: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/10.jpg)
Trachelectomy cases I.Trachelectomy cases I.
IDID AgeAge StgStg ThTh Follow-up grav.Follow-up grav.1.1. 3131 Ib1 (12*3mm)Ib1 (12*3mm) VTRVTR 2x delivery (SC) 2x delivery (SC) 2.2. 2828 Ia1 (7*2mm)Ia1 (7*2mm) VTR+LNDVTR+LND 1x deliver (SC)1x deliver (SC)3.3. 2525 Ia2 (7*3mm)Ia2 (7*3mm) VTR+LNDVTR+LND 1x deliver (SC)1x deliver (SC)4.4. 3434 Ib1 (12*7)Ib1 (12*7) VTR+LNDVTR+LND 1x deliver (SC)1x deliver (SC)5.5. 3636 Ia2 (5*3) Ia2 (5*3) VTRVTR(R1)(R1)TAH+LNDTAH+LND
TR: trachelectomyTR: trachelectomyLND: lymphadenectomyLND: lymphadenectomy
![Page 11: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/11.jpg)
Trachelectomy cases II.Trachelectomy cases II.ID Age Stg Th Follow-up 6. 34 Ia1 (3*1mm) VTR 61mths NED
7. 36 Ib1 (12*8mm) VTR+LND N1! 41mths NED
8. 34 Ib1adeno ATR(R1N1)WM 23mths DOD9. 30 Ia1adeno ATR+LND 39mths NED10. 34 Ib1 ATR(N1)WM
25mths DOD11. 30 Ib1 ATR+LND 17mthsNED
TR: trachelectomyTR: trachelectomyLND: LSC lymphadenectomyLND: LSC lymphadenectomy
![Page 12: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/12.jpg)
Aims of neoadjuvant Aims of neoadjuvant chemoterapy chemoterapy
Prevent spreadPrevent spread Down-stagingDown-staging Tumour-demarcationTumour-demarcation
![Page 13: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/13.jpg)
Modes of administrationModes of administration
Monotherapy or combined Monotherapy or combined chemotherapychemotherapy
CyclicalCyclical Systemic or regionalSystemic or regional
![Page 14: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/14.jpg)
Mechanism of actionMechanism of action
AlkilatingAlkilating Cytoxan,IfosfamidCytoxan,Ifosfamid AntimitoticAntimitotic Vincristin, TaxolVincristin, Taxol AntimetabolitesAntimetabolitesMethotrexat, FluorouracilMethotrexat, Fluorouracil AntibioticsAntibiotics Bleomycin, Mitomycin, Bleomycin, Mitomycin,
Adriamycin, PeplomycinAdriamycin, Peplomycin Anticytosceletal Anticytosceletal Taxanes Taxanes OtherOther Cisplatin, CarboplatinCisplatin, Carboplatin
![Page 15: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/15.jpg)
Side-effectsSide-effects
ImmediateImmediate endothel necrosisendothel necrosis
EarlyEarly nausea, vomiting, emesis, nausea, vomiting, emesis, myelodepressionmyelodepression
LateLate alopecia,myelodepression,mucositis,alopecia,myelodepression,mucositis,fibrosis pulmonum, neuritis, fibrosis pulmonum, neuritis, diarrhoea,insuff.hepatorenalis, diarrhoea,insuff.hepatorenalis,
cardiomyopathycardiomyopathy
![Page 16: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/16.jpg)
ProtocolProtocol BIPBIP Bleomycin 30mg/12hrsBleomycin 30mg/12hrs 1.day1.day
CDDP 50mg/m2CDDP 50mg/m22.day2.day
Ifosfamid 3 g/m2Ifosfamid 3 g/m2 3.day3.dayMesna 1g/m2 3*Mesna 1g/m2 3*
3-weekly3-weekly
![Page 17: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/17.jpg)
Neoadjuvant BIP Neoadjuvant BIP chemoterapychemoterapyat UD MHSCat UD MHSC
Ib2-IIb N=23 (out of 100 WM)Ib2-IIb N=23 (out of 100 WM) Mean age 50 yrs (33-66)Mean age 50 yrs (33-66) Adenoca = 2, Planocell = 21Adenoca = 2, Planocell = 21 pTy0N0M0=7pTy0N0M0=7 pTy1-3N1M0=6pTy1-3N1M0=6
![Page 18: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/18.jpg)
Female genital cancerFemale genital cancerIncidence (n/100000/yr) in Incidence (n/100000/yr) in
20082008Eurostat, 2010Eurostat, 2010
EUREUR HUHU
BreastBreast 88,488,4 78,778,7
CervixCervix 12,812,8 19,519,5
CorpusCorpus 16,716,7 17,717,7
OvaryOvary 13,713,7 13,713,7
![Page 19: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/19.jpg)
Female genital cancerFemale genital cancerMortality (n/100000/yr) in Mortality (n/100000/yr) in
20082008Eurostat, 2010Eurostat, 2010
EUREUR HUHU
BreastBreast 24,324,3 22,622,6
CervixCervix 5,25,2 5,75,7
CorpusCorpus 3,83,8 3,63,6
OvaryOvary 7,97,9 8,38,3
![Page 20: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/20.jpg)
Gynecologic tumorsGynecologic tumorsStaging in generalStaging in general
II localized to organ of localized to organ of originorigin
IIII spread to adjacent spread to adjacent tissuestissues
IIIIII regional lymphatic regional lymphatic spreadspread
IVIV distant metastasisdistant metastasis
![Page 21: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/21.jpg)
Endometrial cancer in Endometrial cancer in Hungary in 2005Hungary in 2005
1213 new cases1213 new cases
219 deaths219 deaths
![Page 22: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/22.jpg)
Corpus cancer - OriginCorpus cancer - Origin
Endometrial cancerEndometrial cancer Endometrial stroma sarcomaEndometrial stroma sarcoma Myometrial sarcomaMyometrial sarcoma
![Page 23: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/23.jpg)
Gynecologic tumorsGynecologic tumorsStaging in generalStaging in general
II localized to organ of localized to organ of originorigin
IIII spread to adjacent spread to adjacent tissuestissues
IIIIII regional lymphatic regional lymphatic spreadspread
IVIV distant metastasisdistant metastasis
![Page 24: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/24.jpg)
Endometrial cancer Endometrial cancer stage-distribution (%)stage-distribution (%)
0
10
20
30
40
50
60
70
80
I II III IV
Frequency
![Page 25: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/25.jpg)
Age distribution in endometrial Age distribution in endometrial cancercancer N=817N=817
05
1015202530354045
30 35 40 45 50 55 60 65 70 75 80 85 90
Age (yr)
N
Frequency
![Page 26: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/26.jpg)
Histologic type distributionHistologic type distribution
EndometrioidEndometrioid 82 82 %%
AdenosquamousAdenosquamous 6 %6 %
MucinousMucinous 1%1%
Papillary serousPapillary serous 4 %4 %
Clear cellClear cell 2 %2 %
SquamousSquamous 0,5 %0,5 %
OtherOther 4,5 %4,5 %
![Page 27: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/27.jpg)
PathogenesisPathogenesis
Estrogen-dependent proliferationEstrogen-dependent proliferation Lack of gestogen-suppressionLack of gestogen-suppression Insulin-resistance Insulin-resistance Tumorsuppressor-mutations Tumorsuppressor-mutations
(p53,p21)(p53,p21) Extragonadal aromatase-activityExtragonadal aromatase-activity
![Page 28: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/28.jpg)
Characteristic associated Characteristic associated disorders and medical disorders and medical
historyhistory HypertensionHypertension Diabetes mellitusDiabetes mellitus ObesityObesity PCOPCO Anovulatory cyclesAnovulatory cycles Less pregnanciesLess pregnancies Shorter lactationShorter lactation
![Page 29: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/29.jpg)
DiagnosisDiagnosis
Histologic verificationHistologic verification
![Page 30: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/30.jpg)
Prognostic factors Prognostic factors in endometrial cancerin endometrial cancer
AgeAge Histologic typeHistologic type Degree of differentiationDegree of differentiation Depth of myometrial Depth of myometrial
invasioninvasion Cervical involvementCervical involvement Adnexal involvementAdnexal involvement Lymphatic spreadLymphatic spread Distant metastasisDistant metastasis
![Page 31: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/31.jpg)
Pathologic stagingPathologic staging(changes in 2010)(changes in 2010)
IaIa Localized to endometriumLocalized to endometrium
IbIb (Ia)(Ia) Superficial myometrium-Superficial myometrium-invasioninvasion
IcIc (Ib)(Ib) Deep myometrium-invasionDeep myometrium-invasion
IIa IIa (Ib)(Ib) Spread to cervix mucosaSpread to cervix mucosa
IIb IIb (II)(II) Cervical stromal involvementCervical stromal involvement
IIIaIIIa Adnex/serosa involvementAdnex/serosa involvement
IIIbIIIb Vaginal metastasisVaginal metastasis
IIIc IIIc (IIIc1/IIIc2)(IIIc1/IIIc2) Pelv./paraaort. nodal Pelv./paraaort. nodal metastasismetastasis
IVaIVa Bladder/rectum invasionBladder/rectum invasion
IVbIVb Distant metastasisDistant metastasis
![Page 32: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/32.jpg)
I
II (FIGO 2010)
IB (FIGO 2010)
IB (FIGO 2010)
IA (FIGO 2010)
IIIc2 (FIGO 2010)
IIIc1 (FIGO 2010)
![Page 33: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/33.jpg)
![Page 34: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/34.jpg)
![Page 35: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/35.jpg)
![Page 36: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/36.jpg)
TreatmentTreatment
Surgery (TAH+BSOSurgery (TAH+BSO++lymphadenect)lymphadenect) Radiotherapy (adjuvant or primary)Radiotherapy (adjuvant or primary) Chemotherapy (adjuvant or Chemotherapy (adjuvant or
primary)primary) Gestogen therapy (adjuvant)Gestogen therapy (adjuvant)
![Page 37: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/37.jpg)
Five-year survivalFive-year survivalSurgerySurgery 84%84%
RadiotherapyRadiotherapy 45,3%45,3%
RadiosurgeryRadiosurgery 83,6%83,6%
Surgery+RadiotherapySurgery+Radiotherapy 82,4%82,4%
Surgery+ChemotherapySurgery+Chemotherapy59,8%59,8%
Hormonal therapyHormonal therapy 42,9%42,9%
![Page 38: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/38.jpg)
PreventionPrevention
Combined oral contraceptives Combined oral contraceptives >10yrs>10yrs
Bodyweight controlBodyweight control Oncological surveillanceOncological surveillance Progestogenic oppositionProgestogenic opposition
![Page 39: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/39.jpg)
Cases of endometrial cancer Cases of endometrial cancer at UD MHSC n=1368at UD MHSC n=1368
0
10
20
30
40
50
60
70
80
90
Count
20 30 40 50 60 70 80 90 100AGE
Histogram
![Page 40: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/40.jpg)
Endometrial cancer young Endometrial cancer young casescases
All casesAll cases 13681368
Age <45 yrsAge <45 yrs 9696
Age <45 yrs without hysterectomyAge <45 yrs without hysterectomy 66
![Page 41: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/41.jpg)
Endometrial cancer cases Endometrial cancer cases at UD MHSC without at UD MHSC without
hysterectomyhysterectomy
IDID AgeAge StgStg Th Th GravGrav Follow-upFollow-up
1.1. 2727 IaG1IaG1 6*Cu 6*Cu P2 P2 25yrs PD25yrs PD
2.2. 4343 IaG1IaG1 2*Cu 2*Cu 00 8yrs NED8yrs NED
3.3. 2929 IIG1IIG1 Cu+2*IC Cu+2*IC 00 24yrs ov.ca.III/b24yrs ov.ca.III/b
4.4. 2525 IaG1IaG1 Cu+5*IC Cu+5*IC 00 4yrs PCOD4yrs PCOD
5.5. 3030 IaG1IaG1 Cu+MPA Cu+MPA 00 2yrs NED2yrs NED
6.6. 2323 IaG1IaG1 Cu+MPA Cu+MPA 00 1yr NED 1yr NED
![Page 42: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/42.jpg)
Ovarian cancerOvarian cancer
EpidemiologyEpidemiology Incidence, mortalityIncidence, mortality StagingStaging Diagnostic work-upDiagnostic work-up Debulking surgery (pathological staging)Debulking surgery (pathological staging) Adjuvant chemotherapyAdjuvant chemotherapy Neoadjuvant chemotherapyNeoadjuvant chemotherapy
![Page 43: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/43.jpg)
![Page 44: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/44.jpg)
![Page 45: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/45.jpg)
Vulval carcinoma, Vulval carcinoma, EpidemiologyEpidemiology
Disease of the elderlyDisease of the elderly 2-3% of all genital cencers2-3% of all genital cencers In Hungary 122 new cases in 1994, 205 in In Hungary 122 new cases in 1994, 205 in
20052005 90% squamous90% squamous
![Page 46: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/46.jpg)
FIGO stagesFIGO stages
IaIa <2cm, <2cm, <<1mm invasion1mm invasion IbIb <2cm, >1mm invasion<2cm, >1mm invasion IIII >2cm>2cm IIIIII urethra/vagina/perineum/anus urethra/vagina/perineum/anus
involvement, unilateral inguinal metinvolvement, unilateral inguinal met IVaIVa rectal/bladder involvement, rectal/bladder involvement,
bilateral inguinal metbilateral inguinal met IVbIVb distant metdistant met
![Page 47: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/47.jpg)
TNM stagesTNM stages FIGOFIGO TT NN MM IaIa 1a1a 00 00 IbIb 1b1b 00 00 IIII 22 00 00 IIIIII 1-31-3 0-10-1 00 IVaIVa 1-31-3 22 00 IVaIVa 44 0-20-2 00 IVbIVb 1-41-4 0-20-2 11
![Page 48: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/48.jpg)
Macroscopic appearanceMacroscopic appearance
SuperficialSuperficial 5-15%5-15% ExophyticExophytic 40%40% EndophyticEndophytic 45%45%
![Page 49: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/49.jpg)
SpreadSpread
1.1. Inguinal and femoral lymph Inguinal and femoral lymph nodesnodes
2.2. Cloquet/Rosenmüller nodesCloquet/Rosenmüller nodes
3.3. Parailiac nodesParailiac nodes
![Page 50: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/50.jpg)
Evolution of surgical Evolution of surgical treatmenttreatment
Parré-JonesParré-Jones Inguinali radiotherapyInguinali radiotherapy <1 mm invasion warrants no <1 mm invasion warrants no
nodal diseasenodal disease Sentinel nodesSentinel nodes Neville HackerNeville Hacker
![Page 51: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/51.jpg)
Progression free survival Progression free survival improved by improved by
lymphadenectomylymphadenectomy
0
,2
,4
,6
,8
1
0 10
20
30
40
50
60Műtét óta eltelt idő hónapokban kifejezve
Túlé
lési
hán
yad
0
,2
,4
,6
,8
1
0 10
20
30
40
50
60Műtét óta eltelt idő hónapokban kifejezve
Túlé
lési
hán
yad Vulvectomy+lymphadenectomy -
Vulvectomy
![Page 52: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/52.jpg)
Overall survival improved Overall survival improved by lymphadenectomyby lymphadenectomy
0
,2
,4
,6
,8
1
Túlé
lésih
án
yad
0 10
20
30
40
50
60Műtét óta eltelt idő hónapokban kifejezve
0
,2
,4
,6
,8
1
Túlé
lésih
án
yad
0 10
20
30
40
50
60Műtét óta eltelt idő hónapokban kifejezve
Vulvectomy+lymphadenectomy -
Vulvectomy
![Page 53: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/53.jpg)
![Page 54: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/54.jpg)
![Page 55: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/55.jpg)
![Page 56: Gynaecological tumours Prof.Dr.Póka Róbert Female genital cancer incidence (N/100.000 population/year) in 2008 Eurostat, 2010 EURHU Breast88,478,7 Cervix12,819,5](https://reader034.vdocuments.us/reader034/viewer/2022050908/56649e865503460f94b88c9b/html5/thumbnails/56.jpg)
Summary of treatment for Summary of treatment for vulval cancervulval cancer
Survival of vulval cancer with no spread to urinary or GI tracts is Survival of vulval cancer with no spread to urinary or GI tracts is improved by adding lymphadenectomy to wide excision of improved by adding lymphadenectomy to wide excision of primary tumour.primary tumour.
Advanced or regional metastatic disease treated with Advanced or regional metastatic disease treated with radiotherapyradiotherapy
Disseminated tumours require chemotherapyDisseminated tumours require chemotherapy